Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP

Sobi

Status and phase

Completed

Phase 3

Conditions

Immune Thrombocytopenia

Treatments

Drug: Avatrombopag Oral Tablet

Study type

Interventional

Funder types

Industry

Identifiers

NCT05369208

AVA-ITP-307

Details and patient eligibility

About

Evaluate the efficacy, safety, and PK of avatrombopag given for 26 weeks in Japanese adults with chronic immune thrombocytopenia (ITP).

Full description

This Phase 3, multicenter, open label study will evaluate the efficacy, safety, and population pharmacokinetics (PK) of avatrombopag in Japanese adults with chronic ITP. At least 19 subjects will be enrolled. The study will consist of 3 phases: Pre-enrollment, Primary Investigation, and Extension Phase until market authorization in Japan.

Enrollment

19 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject has a confirmed diagnosis of chronic immune thrombocytopenia (ITP) (≥12 months duration) and has had an insufficient response to a previous ITP treatment, in the opinion of the Investigator.
Subject has an average of 2 platelet counts <30×10^9/L (no single count can be >35×10^9/L). The 2 samples must be obtained ≥48 hours and ≤2 weeks apart.

Exclusion criteria

Subjects with known secondary immune thrombocytopenia (e.g., with known Helicobacter pylori-induced ITP, subjects infected with known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) or subjects with known systemic lupus erythematosus).
Subjects with known inherited thrombocytopenia (e.g., Myosin Heavy Chain 9 (MYH-9) disorders) or hereditary thrombophilic disorders (e.g., Factor V Leiden, antithrombin III deficiency).
History of myelodysplastic syndrome (MDS).
History of arterial or venous thrombosis.
Subjects with a history of significant cardiovascular disease (e.g., congestive heart failure (CHF) New York Heart Association Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [e.g., atrial fibrillation], angina, coronary artery stent placement, angioplasty, coronary artery bypass grafting).
Subjects with a history of cirrhosis, portal hypertension, or chronic active hepatitis.
Subjects with concurrent malignant disease or receiving cytotoxic chemotherapy for a reason other than ITP treatment.
Use of immunoglobulins (IVIg and anti-D) or corticosteroid rescue therapy within 1 week of Day 1/Baseline.
Splenectomy or use of rituximab within 12 weeks of Day 1/Baseline.
Use of romiplostim or eltrombopag within 1 week of Day 1/Baseline.
Use of chronic corticosteroid treatment or azathioprine within 4 weeks of Day 1/Baseline, unless receiving a stable dose for at least 4 weeks.
Use of mycophenolate mofetil, cyclosporin A, or danazol within 4 weeks of Day 1/Baseline, unless receiving a stable dose for at least 12 weeks.
Use of cyclophosphamide or vinca alkaloid regimens within 4 weeks of Baseline Visit.
Currently receiving moderate or strong dual inhibitors/inducers of CYP2C9 and CYP3A4.
Serum creatinine ≥1.5× the upper limit of normal (ULN).
Serum bilirubin ≥2×ULN.
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3×ULN.
Females who are pregnant (positive beta-human chorionic gonadotropin (β-hCG) test) or breastfeeding.
Received treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) before Day 1/Baseline.